Ethics Watchdog Urges Investigation Into Top Health Official, Alleging Conflict of Interest Over Hormone Therapy Policy

A nonpartisan principles guard dog group has actually requested for an examination into whether a leading Department of Health and Human Services main breached principles laws after a current ProPublica examination exposed actions specialists called “worrying” and an “apparent dispute of interest.”

Alicia Jackson, who heads the Advanced Research Projects Agency for Health, openly backed a modification to federal health policy on hormonal agent replacement treatments while owning stock in a business that supplies access to menopause treatments.

In a letter to the department’s inspector basicthe Campaign Legal Center likewise questioned whether Jackson appropriately determined approximately $400 million in underlying possessions held by her partner’s financial investment company. The center’s evaluation recognized an extra prospective dispute– financial investments in a 2nd company that supplies hormonal agent treatments for menopause.

Jackson, who heads the HHS company that invests taxpayer cash in medical innovation and research study, was just recently put on administrative leave, though health authorities have actually not openly discussed why.

In its letter, the Campaign Legal Center mentioned the ProPublica examination that discovered Jackson spoke at an HHS interview last November and was estimated in a department press release revealing the choice to eliminate “black box cautions” from hormonal agent replacement treatment items.

At the time, Jackson owned a minimum of $115,000 in stock and an unidentified quantity of stock choices in Evernow, a business she established that links females to hormonal agent replacement treatments, according to her monetary disclosures

It’s uncertain what function, if any, Jackson played in the choice to drop the requirement to show a black box caution, the most severe kind of federal security caution. The Food and Drug Administration manages drugs. And an FDA panel of specialists had actually suggested ending the requirement months before Jackson became her company’s director in October 2025.

Still, principles professionals kept in mind that federal law restricts civil servant from getting involved “personally and significantly” in matters that might affect their individual financial resources– even making declarations at an interview or in a press release.

The Campaign Legal Center asked the inspector general to analyze whether Jackson broke federal principles laws by stopping working to recuse herself. Neither Jackson nor the HHS will state whether she got a conflict-of-interest waiver before taking part in the policy statement.

“Americans have a right to understand that federal government choices are not being made to benefit a federal worker’s monetary interests,” the company composed.

The center likewise asked the inspector general to figure out if Jackson stopped working to totally and properly divulge her and her partner’s monetary interests in personal mutual fund.

ProPublica’s examination discovered that Jackson reported she and her other half owned more than 60 equity capital and personal equity funds that she stated do not divulge their holdings to financiers. These consist of a minimum of 13 funds handled by 137 Ventures, an equity capital company co-founded by her hubby, Alex JacobsonThe business buys a wide variety of markets, consisting of health care, digital health and medical gadget business.

Principles specialists stated the funds might position a severe dispute of interest if the hidden services got grants or agreements from her firm.

The Campaign Legal Center’s evaluation of Jackson’s disclosures determined among those funds– 137 Ventures IV LP– as a financier in Thirty Madison Inc., a virtual health care business. Thirty Madison owns a subsidiary that supplies hormonal agent replacement treatments for females experiencing menopause signs. Jackson’s disclosures do disappoint her divesting from the fund before the black box alerting statement, the center stated.

Under federal law, monetary disclosure kinds submitted by federal authorities like Jackson should then be licensed by principles personnel as abiding by the law. Jackson’s 2 monetary disclosures– submitted last October and 2 months back– stay uncertified.

HHS’ inspector general’s workplace would not verify or reject whether it is examining Jackson. The inspector general, T. March Bell, was among almost 100 appointees verified by the Senate in a December 2025 party-line votePresident Donald Trump fired the previous inspector basic simply days into the president’s 2nd term.

ProPublica likewise asked for actions from HHS, Jackson, Jacobson and 137 Ventures, however none commented. In a declaration to ProPublica last month, an HHS representative stated that while Jackson was on leave the company would “examine the realities before figuring out any modification in her status. HHS needs all authorities to abide by federal principles laws, policies, and policies.”

Jackson was selected by Trump as her firm’s 2nd director and sworn in on Oct. 20, 2025. The company, produced 3 years previously to stimulate advanced biomedical research study and innovations, has a $1.5 billion spending plan. It has actually provided various agreements and grants, consisting of $160 million for hereditary medications combating unusual illness and $144 million to study existing treatments for age-related health problems.

Jackson’s disclosures are amongst 2,400 included last month to ProPublica’s Trump Team Financials databasea searchable tool introduced in March. The records information the financial resources of more than 2,300 authorities selected by Trump. Because in 2015, we’ve asked for disclosure records from 127 federal companies and the White House. Disclosures from approximately 1,500 appointees stay unreleased.